182.25
0.45 (0.25%)
| Previous Close | 181.80 |
| Open | 182.47 |
| Volume | 183,383 |
| Avg. Volume (3M) | 418,142 |
| Market Cap | 5,855,284,736 |
| Price / Sales | 8.34 |
| Price / Book | 53.87 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | -15.90% |
| Operating Margin (TTM) | -19.49% |
| Diluted EPS (TTM) | -3.12 |
| Quarterly Revenue Growth (YOY) | 20.30% |
| Total Debt/Equity (MRQ) | 848.67% |
| Current Ratio (MRQ) | 5.71 |
| Operating Cash Flow (TTM) | 47.53 M |
| Levered Free Cash Flow (TTM) | 26.95 M |
| Return on Assets (TTM) | -4.37% |
| Return on Equity (TTM) | -111.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | iRhythm Technologies, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 0.5 |
| Average | -0.75 |
|
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 115.08% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 244.00 (Needham, 33.88%) | Buy |
| Median | 213.50 (17.15%) | |
| Low | 175.00 (Evercore ISI Group, -3.98%) | Hold |
| Average | 215.50 (18.24%) | |
| Total | 8 Buy, 2 Hold | |
| Avg. Price @ Call | 181.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 31 Oct 2025 | 215.00 (17.97%) | Buy | 187.30 |
| 13 Oct 2025 | 195.00 (7.00%) | Buy | 177.37 | |
| Canaccord Genuity | 31 Oct 2025 | 212.00 (16.32%) | Buy | 187.30 |
| 29 Sep 2025 | 193.00 (5.90%) | Buy | 169.50 | |
| Citigroup | 31 Oct 2025 | 242.00 (32.78%) | Buy | 187.30 |
| 07 Oct 2025 | 205.00 (12.48%) | Buy | 177.62 | |
| Goldman Sachs | 31 Oct 2025 | 202.00 (10.84%) | Hold | 187.30 |
| 01 Oct 2025 | 180.00 (-1.23%) | Hold | 167.45 | |
| JP Morgan | 31 Oct 2025 | 240.00 (31.69%) | Buy | 187.30 |
| Needham | 31 Oct 2025 | 244.00 (33.88%) | Buy | 187.30 |
| 28 Aug 2025 | 193.00 (5.90%) | Buy | 171.47 | |
| Truist Securities | 15 Oct 2025 | 205.00 (12.48%) | Buy | 175.67 |
| Baird | 10 Oct 2025 | 220.00 (20.71%) | Buy | 176.20 |
| Evercore ISI Group | 07 Oct 2025 | 175.00 (-3.98%) | Hold | 177.62 |
| 23 Sep 2025 | 185.00 (1.51%) | Hold | 175.46 | |
| B of A Securities | 20 Aug 2025 | 200.00 (9.74%) | Buy | 163.20 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Nov 2025 | Announcement | iRhythm Technologies to Participate in Upcoming Investor Conferences |
| 30 Oct 2025 | Announcement | iRhythm Technologies Announces Third Quarter 2025 Financial Results |
| 16 Oct 2025 | Announcement | iRhythm Technologies to Report Third Quarter 2025 Financial Results on October 30, 2025 |
| 29 Aug 2025 | Announcement | AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service |
| 29 Aug 2025 | Announcement | AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service |
| 20 Aug 2025 | Announcement | iRhythm Technologies to Participate in Upcoming Investor Conferences |
| 18 Aug 2025 | Announcement | AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |